[Immunocyanin in urothelial bladder cancer

Larrea Bonavento N, Ciapponi A, Pichon-Riviere A, Augustovski F, García Martí S, Alcaraz A, Bardach A.
Record ID 32018001541
Original Title: Inmunocianina para cáncer urotelial de vejiga
Authors' recommendations: No studies directly comparing intravesical therapy with immunocyanin with intravesical therapy with the bacillus Calmette-Guérin (BCG) for non-infiltrating bladder cancer relapse have been found. Moderate-quality evidence has not proved that intravesical therapy with immunocyanin is better than intravesical therapy with mitomycin C in disease relapse prevention. The clinical practice guidelines consulted do not mention its use. In Argentina, it is covered by the Unique Reimbursement System. The rest of the state and private health funders consulted internationally do not cover it. No cost-effectiveness studies related to this technology for this indication have been found.
Project Status: Completed
Year Published: 2019
URL for published report: https://www.iecs.org.ar/home-ets/
English language abstract: An English language summary is available
Publication Type: Not Assigned
Country: Argentina
MeSH Terms
  • Urinary Bladder Neoplasms
  • Hemocyanins
  • Adjuvants, Immunologic
  • Antibiotics, Antineoplastic
Organisation Name: Institute for Clinical Effectiveness and Health Policy
Contact Address: Dr. Emilio Ravignani 2024, Buenos Aires - Argentina, C1414 CABA
Contact Name: info@iecs.org.ar
Contact Email: info@iecs.org.ar
Copyright: Institute for Clinical Effectiveness and Health Policy (IECS)
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.